Tumor-induced osteomalacia in association with PTEN-negative Cowden syndrome

J. A. Berglund, R. I. Gafni, F. Wodajo, E. W. Cowen, D. El-Maouche, R. Chang, C. C. Chen, L. C. Guthrie, A. A. Molinolo, M. T. Collins

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic condition in which phosphaturic mesenchymal tumors (PMTs) secrete high levels of fibroblast growth factor 23 (FGF23) into the circulation. This results in renal phosphate wasting, hypophosphatemia, muscle weakness, bone pain, and pathological fractures. Recent studies suggest that fibronectin-fibroblast growth factor receptor 1 (FN1-FGFR1) translocations may be a driver of tumorigenesis. We present a patient with TIO who also exhibited clinical findings suggestive of Cowden syndrome (CS), a rare autosomal dominant disorder characterized by numerous benign hamartomas, as well as an increased risk for multiple malignancies, such as thyroid cancer. While CS is a clinical diagnosis, most, but not all, harbor a mutation in the tumor suppressor gene PTEN. Genetic testing revealed a somatic FN1-FGFR1 translocation in the FGF23-producing tumor causing TIO; however, a germline PTEN mutation was not identified. To our knowledge, this is the first reported case of concurrent TIO and CS.

Original languageEnglish (US)
Pages (from-to)993-997
Number of pages5
JournalOsteoporosis International
Volume29
Issue number4
DOIs
StatePublished - Apr 1 2018

Keywords

  • Cowden syndrome
  • FGF23
  • FN1-FGFR1
  • PTEN
  • Phosphaturic mesenchymal tumor
  • Tumor-induced osteomalacia

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Tumor-induced osteomalacia in association with PTEN-negative Cowden syndrome'. Together they form a unique fingerprint.

Cite this